Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors.
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. Eur J Intern Med. 2022 09; 103:95-99.